In a recent article in PLOS One, Don van Ravenzwaaij and John Ioannidis argue that Bayes factors should be preferred to significance testing (p-values) when assessing the effectiveness of new drugs. At his blogsite The 20% Statistician, Daniel Lakens argues…
Read More